Please use this identifier to cite or link to this item:
Title: COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
Author: Garrigós, Laia
Saura, Cristina
Martinez-Vila, Clara
Zambelli, Alberto
Bower, Mark
Pistilli, Barbara
Lambertini, Matteo
Ottaviani, Diego
Diamantis, Nikolaos
Lumsden, Ailsa
Pernas, Sònia
Generali, Daniele
Seguí, Elia
Viñas, Gemma
Felip, Eudald
Sánchez, Ana
Rizzo, Gianpiero
Santoro, Armando
Cortellini, Alessio
Perone, Ylenia
Chester, John
Iglesias, María
Betti, Marta
Vincenzi, Bruno
Libertini, Michela
Mazzoni, Francesca
Zoratto, Federica
Berardi, Rossana
Guida, Annalisa
Wuerstlein, Rachel
Loizidou, Angela
Sharkey, Rachel
Aguilar Company, Juan
Matas, Marta
Saggia, Chiara
Chiudinelli, Lorenzo
Colomba-Blameble, Emeline
Galazi, Myria
Mukherjee, Uma
Van Hemelrijck, Mieke
Marin, Mar
Strina, Carla
Prat Aparicio, Aleix
Pla, Helena
Ciruelos, Eva
Bertuzzi, Alexia
Mastro, Lucia del
Porzio, Giampiero
Newsom-Davis, Thomas
Ruiz, Isabel
Delany, Maria Belen
Krengli, Marco
Fotia, Vittoria
Viansone, Alessandro
Chopra, Neha
Romeo, Margarita
Salazar Soler, Ramón
Pérez Catalán, Ignacio
D’Avanzo, Francesca
Franchi, Michela
Milani, Manuela
Pommeret, Fanny
Tucci, Marco
Pedrazzoli, Paolo
Harbeck, Nadia
Ferrante, Daniela
Pinato, David J.
Gennari, Alessandra
Keywords: Càncer de mama
Avaluació de resultats (Assistència mèdica)
Breast cancer
Outcome assessment (Medical care)
Issue Date: 1-Jan-2021
Publisher: SAGE Publications
Abstract: Background: cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: we report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population. Results: we included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications. Conclusion: in the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.
Note: Reproducció del document publicat a:
It is part of: Therapeutic Advances in Medical Oncology, 2021, vol. 13, p. 175883592110534
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
17588359211053416.pdf328.66 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons